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ABSTRACT
Clinical trials play important roles in drug development but often
suffer from expensive, inaccurate and insufficient patient recruit-
ment. The availability of massive electronic health records (EHR)
data and trial eligibility criteria (EC) bring a new opportunity to data
driven patient recruitment. One key task named patient-trial match-
ing is to find qualified patients for clinical trials given structured
EHR and unstructured EC text (both inclusion and exclusion crite-
ria). How tomatch complex EC text with longitudinal patient EHRs?
How to embed many-to-many relationships between patients and
trials? How to explicitly handle the difference between inclusion
and exclusion criteria? In this paper, we proposed CrOss-Modal
PseudO-SiamEse network (COMPOSE) to address these challenges
for patient-trial matching. One path of the network encodes EC
using convolutional highway network. The other path processes
EHR with multi-granularity memory network that encodes struc-
tured patient records into multiple levels based on medical ontology.
Using the EC embedding as query, COMPOSE performs attentional
record alignment and thus enables dynamic patient-trial matching.
COMPOSE also introduces a composite loss term to maximize the
similarity between patient records and inclusion criteria while min-
imize the similarity to the exclusion criteria. Experiment results
show COMPOSE can reach 98.0% AUC on patient-criteria matching
and 83.7% accuracy on patient-trial matching, which leads 24.3%
improvement over the best baseline on real-world patient-trial
matching tasks.
CCS CONCEPTS
• Computing methodologies → Neural networks; Learning
latent representations; •Applied computing→Health infor-
matics.
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1 INTRODUCTION
Clinical trials with annual market of over 46 billion USD are the
only established process for developing new treatments for diseases.
But trials often suffer from expensive, inaccurate and insufficient
patient recruitment. Many trials struggle to acquire the required
number of patients. Moreover 50% of trials delayed due to patient
recruitment issues while some trials are unable to find sufficient
patients to begin the trial at all [23]. For example, Campbell et
al. [4] reported that one-third of publicly funded trials required
time extensions due to insufficient enrollment. It was also reported
that 25% of cancer trials failed to enroll sufficient patients [26].
Even with sufficient patient, the recruitment cost is high, estimated
around 6000 to 7500 USD per patient [20].
Figure 1: An illustration of patient-trial matching.
Automated patient-trial matching brings a new opportunity to
optimize the trial recruitment process. The key is to find qualified
patients for clinical trials given patient’s longitudinal electronic
health records (EHR) and trial eligibility criteria (EC) described as
both inclusion and exclusion criteria, as shown in Fig.1. Over the
years, rule based retrieval systems and lately a deep embedding
model were developed to match patients for trials. Rule based sys-
tems either rely on large amount of human annotations [16, 29]
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or train supervised learning classifiers to extract rules [3], or com-
bined machine learning and rule-based methods to generate SQL
queries for ECs [32]. However, they often yield poor recall due
to morphological variants and inadequate rule coverage. More re-
cently, DeepEnroll [34] was proposed as a deep embedding model to
predict whether a patient is eligible for a trial. It jointly embeds and
aligns medical concepts derived from patient data and EC onto the
same embedding space, and then perform simple similarity match
of patients to trials based on the aligned embeddings. However,
DeepEnroll ignores the difference between inclusion and exclusion
criteria, which can lead to criteria mismatch. In general, here are
the key open challenges for patient trial matching:
(1) Multi-granularity medical concept. Unstructured ECs often
encode more general disease concepts due to heterogeneity of
disease manifestation [11], while structured patient EHR often
represent patient conditions using more specific medical codes.
For example, a patient with pleuropericardial adhesion on EHR
data can be recruited to a trial that require more general car-
diovascular diseases. It is nontrivial to match medical concepts
with heterogeneous granularity in different data modalities.
(2) Many-to-many relationship between patients and trials.
In practice, each patient may enroll more than one trial and vice
versa. Since each trial generally focus on certain diseases, the
semantic distance between trials even ECs may be large. How-
ever, all existing works align the patient embedding to different
trial embeddings, which may confuse the embed function and
lead to inferior matching results.
(3) Explicit Inclusion/Exclusion Criteria Handling. Trial ECs
comprise inclusion and exclusion criteria. They describe what
are desired and unwanted from the targeted patients. Existing
approaches did not explicitly differentiate these two criteria,
which may significantly affect the matching accuracy.
To address these challenges, we propose CrOss-Modal Pseudo-
Siamese (COMPOSE) for patient trial matching, which has the follow-
ing contributions:
(1) Taxonomies guided multi-granularity medical concept
embedding. To matchmedical concepts of heterogeneous gran-
ularity, we augment the medical codes in patient’s records with
their textual descriptions and hierarchical taxonomies, such
that concepts can be embedded in both finer and more coarse
levels to better align detailed medical codes in EHR and medical
concepts with various granularity.
(2) Attentional record align anddynamic patient-trialmatch.
Instead of aligning a patient’s entire record to each trial, we
developed an attentive READ mechanism inside of a dynamic
memory network to extract the best matching part of patient
EHR to match with ECs at criteria level.
(3) Differentiating inclusion/exclusion criteria. COMPOSE also
has a composite similarity loss term to explicitly handle the in-
clusion and exclusion criteria separately. It improved the patient-
trial matching based on maximizing the similarity between pa-
tient and inclusion criteria while minimizing the patient and
exclusion criteria in latent space.
We evaluated COMPOSE on real world clinical trial dataset. COMPOSE
significantly outperformed the best state-of-the-art baselines. It
achieved 24.3% relatively higher accuracy over the best baselines
on patient-trial matching tasks.
2 RELATEDWORKS
Patient trial matching can be categorized as rule based systems
and deep embedding based models. Rule based systems try to ex-
tract named entities and relations for trial eligibility criteria (ECs)
and construct rules for identifying patients. They either rely on
large amount of human annotations [16, 29] or train supervised
learning classifiers to extract rules [3], or combined machine learn-
ing and rule-based methods [32] to rules for ECs. For example,
EliXR [29] matches Unified Medical Language System (UMLS) con-
cepts and relations via pre-defined dictionary and regular expres-
sions. Alicante et al. [1] utilized unsupervised clustering methods
for eligible rule extraction. Bustos et al. [3] used naive machine
learning models such as CNN, SVM, and kNN as classifiers for
specific disease EC classification. Yuan et al. proposed a complete
pipeline Criteria2Query [32], which combines machine learning
and rule-based methods to form patient criteria. These methods
often yield poor recall due to morphological variants and inade-
quate rule coverage. Recent years, deep embedding based models
such as DeepEnroll [34] jointly embeds patient records and trial
ECs in the same latent space, and then aligns them using attentive
inference. However, DeepEnroll did not consider the match of dif-
ferent concept granularity nor differentiate inclusion and exclusion
criteria. In the experiment, we compare with Criteria2Query and
DeepEnroll as they are the state of the art methods.
Cross-modal retrieval enables flexible retrieval across different
modalities, such as semantic image-text retrieval [25, 31]. The core
of cross-modal retrieval is how to measure the content similarity.
Among others, Siamese network is a typical structure for uni-modal
retrieval tasks [10, 24]. It consists of two branches of the same
structure and utilizes similar pairs and dissimilar pairs for similarity
learning. Pseudo-Siamese network [14, 28] is more flexible than
Siamese network in the sense that it allows different structures to
receive inputs from different modalities. In this work, we developed
a pseudo-siamese network for patient trial matching task.
3 PROBLEM FORMULATION
Below we define the input data and the modeling problem in this
paper. We summarize the notations in Table. 1.
Definition 1 (Patient Records). In longitudinal EHR data, each
patient can be represented as a sequence of multivariate observa-
tions P = [v1,v2, ...,vT ], whereT is the number of visits. Each visit
is represented byvt = [dt1 , . . . ,dti ,ot1 , . . . ,otj ,pt1 , . . . ,ptk ] with
diagnosis dti ∈ D, medication otj ∈ O and procedure ptk ∈ P.
Here D, O and P are the sets of diseases, medications and pro-
cedures, respectively. For simplicity, we use дt to represent any
medical code (dt ,ot , orpt ) invt . Each patient also has demographic
featuresvd including gender and age.
Definition 2 (Clinical Trials). For each clinical trial, its protocol
C = [c I1, ...,c IM ,cE1 , ...,cEN ] comprises two types of eligibility crite-
ria: inclusion criteria and exclusion criteria. whereM (N ) denotes
the number of inclusion (exclusion) criteria in the trial, c Ii (c
E
i ) de-
notes the i-th inclusion (exclusion) criterion. Each criterion c can
Figure 2: COMPOSE model. (1) Clinical trial EC sentence embedding: First, we use pretrained BERT to generate contextualized
word embeddings for each word in EC sentences. Then we use CNNs to capture semantic features and generate embeddings
for EC sentence. (2) Taxonomy guided multi-granularity medical concept embedding: We use hierarchical memory networks
to store medical concept taxonomies. Different granularity information of concept is stored in different levels of the memory
network. (3) Attentional record align and dynamic patient-trial match: We use learned EC embeddings to attentively visit
the memory network and retrieve the best matching memories m˜. Finally, we use the EC embedding and matched memory
embedding to predict matching result. Meanwhile, we also optimize the distance between two embeddings to differentiate
inclusion and exclusion ECs.
be represented as a sequence of words: c = [w1,w2, ...,wW ], where
W is the number of words in c .
Definition 3 (Medical Taxonomy). The medical taxonomy G
expresses the hierarchy of various medical concepts in the form
of a parent-child relationship including diagnosis taxonomy GD ,
procedure taxonomy GP and medication taxonomy GO . The leaf
nodes in a taxonomy G are detailed medical concepts (e.g. Type
2 diabetes mellitus), while parent nodes represent more general
concepts (e.g. Endocrine, nutritional and metabolic diseases). G can
be built by using well-organized taxonomy of medical concepts (e.g.
ICD1, CCS2 or USC3). We use the notationG to represent a general
taxonomy for medical code дt .
Problem 1 (Patient Criteria Matching). Given a patient’s visit
records P and a set of inclusion or exclusion criteria, we formulate
the patient-criteria matching task as a multi-class classification
problem, which is to classify the matching results between patients
and ECs into three categories: "match", "mismatch", and "unknown"
based on the similarity between patient records and trial criteria:
yˆ(c,P) ∈ {match,mismatch,unknown}.
Problem 2 (Patient Trial Matching). Given a patient’s visit
records P and a clinical trial C that comprises a set of inclusion
or exclusion criteria, we consider a patient and a trial are a match
only if the patient matches (i.e., confirms) all inclusion criteria and
mismatches (i.e., refutes) all exclusion criteria in the trial.
1https://www.cdc.gov/nchs/icd/icd10.htm
2https://www.hcup-us.ahrq.gov/toolssoftware/ccs10/ccs10.jsp
3https://www.wolterskluwercdi.com/drug-data/uniform-system-of-classification-
cross-usc/
Table 1: Notations used in COMPOSE.
Notations short explanation
P patient record sequence
vt multivariate visit record at the t-th visit
vd patient demographic features
дt a medical code invt
GD ,GO ,GP taxonomy for disease, medication and procedure
D,O,P sets of diseases, medications, and procedures
C a clinical trial
c Ii ,c
E
i the i-th inclusion or exclusion criterion
wi the i-th word in a text sequence
e learned EC sentence embedding
mk the memory slot at level k
m˜ retrieved patient embedding
yˆ(c,P),y(c,P) predicted/ ground-truth for criteria c with patient P
4 THE COMPOSEMODEL
This section presents our COMPOSE model (Fig. 2). COMPOSE is a
pseudo-siamese network consists of two branches: 1) a convolu-
tional neural network-based branch to learn trial eligibility criteria
(ECs) embeddings and 2) a taxonomy guided memory network
branch to learn embeddings for patient records (EHR). Then we use
an dynamic alignment and matching module to generate final out-
puts. COMPOSEwill embed two modalities of data from ECs and EHR
into a shared latent space. In particular, we use EC embeddings as
query to read memories in the memory network. Finally, we use the
retrieved EHR embeddings and EC embeddings to jointly predict
matching scores yˆt .
4.1 Trial Eligibility Criteria Embedding
Trial eligibility criteria (ECs) describe the inclusion and exclusion
criteria of clinical trials using unstructured text. To learn embed-
dings for trial ECs, previous works use GloVe [22] or BERT [7] with
max-pooling to obtain a static embedding vector for each criterion.
However, this is not a good way to capture detailed information in
sentences such as numerical values or units. We hope the learned
EC embeddings can retain sentence-level semantics while also cap-
ture important detailed information in sentences. To this end, we
use convolutional neural networks (CNN) to learn EC embedding,
as previous works [13] shows that CNN can generate rich matching
patterns at different levels for semantic matching tasks.
First, we use pretrained BERT to generate contextualized word
embedding for each word of EC. Specifically, we applied the Clinical
BERT [2] pretrained on PubMed4 text resources and MIMIC-III [15]
doctor notes. Concretely, given an EC sentence c = [w1, ...,wN ],
the contextualized embeddings c˜ are calculated as:
c˜ = [w˜1, ..., w˜N ] = BERT ([w1, ...,wN ]) (1)
where N denotes the number of words in the EC sentence and w˜i is
a contextualized word embedding forwi . The final embedding for
the EC sentence is the concatenation of these word embeddings.
Then we use multiple one-dimensional convolutional layers with
different kernel sizes to capture semantics at different granularity
level (four levels in our experiment) [31]. We feed c˜ into the one-
dimensional convolutional layers and concatenate the outputs to
generate a vector x as:
x = [Conv(c˜,k1),Conv(c˜,k2),Conv(c˜,k3),Conv(c˜,k4)] (2)
where Conv denotes the one dimensional convolutional operator
with kernel size k1 to k4. Then we feed x into convolutional high-
way layers, which has been widely used in many natural language
processing tasks to extract text semantics [27, 31]. Particularly, the
outputs of highway networks are calculated as:
u = σ (Conv(x ,k))
v = u ·Conv(x ,k) + x · (1 −u) (3)
where σ denotes the sigmoid activation. We set the stride to 1 and
use same padding to make sure the output dimension of v is the
same as the input dimension of x .
Finally, we use max-over-time pooling [17] to reduce the dimen-
sion and obtain the final embedding e for the EC sentence in current
trial as e = MaxPool(v). Each dimension in e denotes a semantic
feature captured by convolutional filters.
4.2 Taxonomy Guided Patient Embedding
Memory networks are powerful frameworks to process, store and
retrieve information from sequential data [30]. To enable the patient-
trial matching task, we also learn effective patient representation
from patient data (e.g., EHR) by using memory network. In this
work, we developed a hierarchical memory network to leverage
medical taxonomy. This is achieved by allowing each memory slot
to memorize concept on a specific level of the taxonomy.
Formally, given a patient’s EHR data, the t-th visit vt is repre-
sented by three types of medical concepts: diagnosis, medications
4https://www.ncbi.nlm.nih.gov/pubmed
and procedures. We encode each type of code using a separate
memory component. Since each type of concept can be divided into
different levels, from a more general concept to a more specific one.
In this work, we use the Uniform System of Classification (USC) tax-
onomy, a therapeutic classification system, to divide each concept
into four levels. To this end, our patient embedding memory net-
work consists of three separate memory networks to store diagnosis,
medications and procedures respectively. Each memory network
has four memory slots to store information from fine-grained to
coarse levels. This can be represented as:
m = [mD ,mO ,mP ]
= [m1D , ...,m4D ,m1O , ...,m4O ,m1P , ...,m4P ]
(4)
m1x is at the root level (most general), whilem4x is the leaf level
(most specific). Each memory slotmkx is a vector initialized by zero.
At each visit, the values in the memory slots will be updated. Note
that we use four levels because of the specific medical taxonomies
used in the experiment. The method can be easily generalized to
taxonomy of different levels like [5, 8].
Augment medical codes with textual description. It is worth
noting that we do not use the one-hot encoded medical codes as
the input like previous trial matching and other clinical prediction
works do [6, 9, 19, 34]. Because, in clinical trial ECs, medical con-
cepts are described in natural language rather than medical codes.
Therefore, using textual description of medical codes to embed
patients’ EHR can help the model find matched concepts. All the
textual description of each medical concept can be found in the
Uniform System of Classification (USC). For example, we use the
textual description Contact dermatitis and other eczema for the di-
agnosis code 692.9. More specifically each medical concept can be
represented as lists of words, i.e., дt = [w1, ...,wL], where L is the
length of the text description for the code дt . We use BERT with
max-pooling to generate the concept embedding:
д˜t = MaxPool(BERT ([w1, ...,wL])) (5)
Specifically, when the patient have multiple diagnosis / medica-
tions / procedures, we use max-pooling layer to aggregate the final
embedding for each type of codes (i.e., we will obtain three code
embeddings d˜t , o˜t and p˜t ).
Update memories at each visit. Since patients’ EHR are sequen-
tial data, we update the memory slots at each visit. We adopt the
erase-followed-by-add update mechanism in [8, 33]. It allows us
to erase unnecessary information at each visit and then add new
information dynamically. Given the medical code embedding д˜t at
t-th visit, we can obtain its parent code embeddings д˜1t to д˜3t in the
corresponding taxonomy and д˜t is the leaf node д˜4t . For the code at
level k (д˜kt ) and corresponding memory slot (mkG ), we calculate the
erase and add gate as:
eraset = σ (We д˜kt + be ), addt = tanh(Waд˜kt + ba ) (6)
Then we update the memory in the slot as:
mkG  mkG ⊙ (1 − eraset ) + addt (7)
where ⊙ denotes the element-wise product.
4.3 Attentional Record Alignment and
Dynamic Criteria Level Match
Previous patient trial matching works learn an alignment matrix
which map patients’ EHR embeddings and EC embeddings to the
same latent space. However, each patient may enroll more than
one trial and vice versa. Since each trial generally focus on certain
diseases, the semantic distance between trials may be large. Try-
ing to push the patient’s EHR embedding to be close to different
EC embeddings may confuse the embed function, or the patient
embedding could be mapped to near average position of those
EC embeddings. Such situation is similar to the multi-label image
classification case in computer vision [25].
To overcome this problem, we let each EC correspond to the
sub-memories that match current trial best. Concretely, we use the
inclusion criteria embedding eI or exclusion criteria embedding
eE as queries to attentively visit the memory network. Given the
memory slot mkG , the attention weight for current slot ak,G is
calculated as:
ak,G =
exp(mkG
T
MLP(e))∑
x ∈{D,O,P}
∑4
i=1 exp(mix
T
MLP(e))
(8)
where MLP(·) is a multi-layer perceptron to align the dimension
between e andmkG . A large ak,G may indicate that the queried trial
is highly related to the information stored in memory slotmkG .
Given an criteria e , we can obtain the best matching memories
m˜ as:
m˜ =
∑
x ∈{D,O,P}
4∑
i=1
ai,xm
i
x (9)
Specifically, we also use MLP to learn a embedding for the pa-
tient’s demographics as:md = MLP(vd ), wheremd has the same
dimension with m˜. Finally, we concatenate the EHR embedding and
the retrieved memory to predict whether the criteria e matches the
patient as:
yˆ = so f tmax(m˜ ⊕ MLP(md ⊕ e)) (10)
where ⊕ denotes the concatenation operation and we use MLP to
map the criteria and demographics embedding to the same embed-
ding space with m˜.
4.4 Joint learning with Explicit
Inclusion/Exclusion Criteria Handling
During model optimization, in order to maximize the patient-trial
matching as well as to explicit handle the difference between inclu-
sion and exclusion criteria, we designed a composite loss function
with the following loss terms.
Classification Loss. We use a cross-entropy loss term in Eq. 11 to
optimize the classification performance between prediction yˆ and
ground truth y:
Lc = −(yTloд(yˆ) + (1 −y)Tloд(1 − yˆ)) (11)
Inclusion/Exclusion Loss. In addition, we also construct a loss
term to explicitly handle the match between patient embedding
and EC embedding for inclusion criteria and exclusion criteria. The
loss term enables the model to extract different features (e.g. nega-
tion words) in the inclusion/exclusion criteria and thus help decide
whether to include or exclude the patient. Mathematically, this boils
down to minimize the distance between the retrieved patient mem-
ory and the embedding for inclusion criteria (i.e., (eI ,m˜I )) while
maximize the distance between the memory and the embedding for
exclusion criteria (i.e., (eE ,m˜E )). We construct the loss term with
the following pairwise distance loss:
Ld =
{
1 − d(e,m˜I )), i f e is eI
max(0,d(e,m˜E ) − α), i f e is eE
(12)
where d(·, ·) is the similarity function between two vectors. In this
work we use the cosine similarity function to measure the distance
between two modalities of data. Here α is a hyper-parameter which
denotes the minimum distance between the embedding of exclusion
criteria and the patient memory. If a patient matches an inclusion
criterion, the model will minimize the cosine distance between
the two embeddings to make 1 − d(e,m˜I ) close to 0. If the patient
is excluded by an exclusion criterion, the distance between two
embeddings (i.e.max(0,d(e,m˜E ) − α)) should be no smaller than
α . This allows eI and eE have different distance to m˜ in the latent
embedding space.
Finally, we jointly minimize the loss functions by back propaga-
tion in an end-to-end way as:
L = Lc + Ld (13)
Our COMPOSE algorithm is summarized in Algorithm. 1.
Algorithm 1 The COMPOSE model
Input:
Patient records P = [v1,v2, ...,vT ], a set of inclusion criteria or
exclusion criteria sentences [c1, ...,cN ].
Training:
Initialize all memory slotsm to zero.
for i = 1 to T do
Generate all medical concept invi embedding using Eq. 5
Update corresponding memory slots using Eq. 7 and 6;
end for
for i = 1 to N do
Generate EC sentence embedding c˜i ;
Obtain the convolution results using Eq. 3;
end for
Retrieve the best-matching memories m˜ using Eq. 9 and 8;
Calculate matching results yˆ using Eq. 10;
Update parameters by optimizing the loss in Eq. 11, 12 and 13.
5 EXPERIMENT
We evaluate COMPOSE by comparing against state-of-the-art base-
lines on a real-world patient trial matching dataset. The code of
COMPOSE is publicly available at 5.
5https://github.com/v1xerunt/COMPOSE
5.1 Experimental Setup
Dataset descriptionWe evaluated COMPOSE using the data below.
(1) Clinical Trial Data We randomly selected 590 clinical tri-
als with varying disease domains from publicly available data
source (ClinicalTrials.gov). We extract the inclusion criteria and
exclusion criteria from these trials. In total, we obtain 12, 445
criteria-level (i.e., sentence-level) EC statements.
(2) Patient EHRDataWe extract patient claims data from IQVIA’s
real-world patient database, which can be accessed by request.
In total we have EHR records from 83, 371 patients from 2002
to 2018, where each patient is a match to at least one trial in
the previous extracted trial dataset. The patient information is
encoded in a longitudinal prescription and medical claims data
including diagnosis, procedures and medications.
We label each inclusion/exclusion criterion and their correspond-
ing matched patients’ EHR as "match"/"mismatch". For each crite-
rion, we randomly sample one inclusion criterion and exclusion
criterion from another trial and label them as "unknown". In all we
have 397,321 labelled pairs. The data statistics are in Appendix.
BaselinesWe evaluated COMPOSE against the following baselines.
(1) LSTM+GloVe [12]. We use LSTM to learn the representation
for longitudinal EHR data and use GloVe [22] followed by a max-
pooling layer to learn the sentence embedding for ECs. Then
we concatenate the outputs to predict the matching results.
(2) LSTM+BERT [7] We use LSTM to learn EHR embeddings and
use BERT to learn EC sentence embeddings. Then we concate-
nate the outputs to predict the matching results.
(3) Criteria2Query [32] consists of a systematic information ex-
traction pipeline that uses basic text mining solution (such as
named entity recognition) to parse unstructured text data and
translate them to a set of structured attributes. And then use
these attributes to identify patient cohorts.
(4) DeepEnroll [34] is the previous state-of-the-art deep learning
model for patient trial matching task. The structure of DeepEn-
roll is similar to LSTM+BERT, but it uses MiME [6] instead of
LSTM to learn EHR embedding. DeepEnroll uses an alignment
matrix to predict the matching results.
GloVe and BERT are common models for text-related retriveal tasks.
We use them as our baseline pseudo-siamese structures. In addition
to these baselines, we also perform ablation studies by comparing
COMPOSE against its reduced models:
(1) COMPOSE-MNWe reduce the memory network from COMPOSE.
We use an LSTM model to learn the EHR embedding, and we
use one-hot encoded codes instead of textual decriptions.
(2) COMPOSE-HighwayWe reduce the highway network from COMPOSE.
We use a regular three-layer CNN to learn the trial embedding.
(3) COMPOSE-Ld We reduce the Ld loss term from COMPOSE. We
use just Lc to optimize the model. Such setting will make the
model not explicitly differentiate inclusion criteria and exclu-
sion criteria.
Evaluation strategy and metrics (1) Criteria Level: We use all
labelled patient-criterion pairs to train and evaluate our model. We
follow previous works [34] to use the accuracy score (Accuracy),
area under the receiver operating characteristic curve (AUROC),
and area under the precision-recall curve (AUPRC) to evaluate
model performance. Since the matching task is casted as a multi-
label classification task, we calculate all scores using micro-average.
(2) Trial Level: For trial level matching tasks, if patient A has en-
rolled in trial B, we first obtain all matching results between A
and all criteria in B, then we aggregated the results to get the final
matching results between patient A and trial B. The result is consid-
ered correct when the prediction results between A and all inclusion
criteria in B are "match" and the results between A and all exclusion
criteria are "mismatch". We use the accuracy score to evaluate the
performance. In practice, some inclusion or exclusion criteria can
be too strict to prevent finding patients, yet non-essential thus can
be modified. We choose four threshold (0.7, 0.8, 0.9 and 1) to simu-
late that trial recruiters may loose the restriction to enroll enough
patients. For example, threshold 0.7 means we consider a patient
match the trial when the patient only matches 70% criteria in the
trial.
We fix a test set of 30% patients, and divide the rest of the dataset
into the training set and validation set with a proportion of 90%:10%.
We fix the best model on the validation set and report the perfor-
mance on the test set. We perform five random runs and report
both mean and standard deviation for testing performance except
for Criteria2Query, since it requires no training process.
5.2 Results
We designed experiments to answer the following question.
Q1. How does COMPOSE perform in patient-trial matching?
Q2. How does COMPOSE perform for various disease categories?
Q3. How does COMPOSE perform for trials at each phases?
Q4. Sensitivity of performance for different matching threshold.
Q5. Cases for showing the attentional record align mechanism.
Q1. Performance on Patient Trial Matching
The results for trial-level matching are shown in Table 2. The ac-
curacy score is computed based on 100% matching criteria (i.e. a
patient matches a trial only when the patient matches all inclusion
criteria and mismatches all exclusion criteria in the trial). COMPOSE
significantly outperfoms other state-of-the-art methods. Compared
to the best baseline model DeepEnroll, COMPOSE achieves 24.3% rel-
atively higher accuracy score compared with DeepEnroll and 36.3%
relatively higher accuracy score compared with Criteria2Query .
Table 2: Patient-Trial matching. Performance are measured
by accuracy based on the match of 100% criteria.
Model Accuracy
Baselines
LSTM+GloVe 0.4294±0.010
LSTM+BERT 0.5460±0.008
Criteria2Query 0.6147±-
DeepEnroll 0.6737±0.021
Reduced
COMPOSE-MN 0.7833±0.011
COMPOSE-Highway 0.8102±0.009
COMPOSE-Ld 0.8212±0.010
Proposed COMPOSE 0.8373±0.012
Among all baselines, Criteria2Query and DeepEnroll achieves
better performance. All reduced models of COMPOSE also outper-
forms all baseline models. And the results also show that textual de-
scription enhanced code embeddings and the hierarchical memory
network that performs dynamic matching contributes most to the
performance. Below we also provide the patient criteria matching
results in Table 3. Compared to the best baseline model DeepEnroll,
COMPOSE achieves 8.8% relatively higher accuracy, 4.7% higher AU-
ROC and 3.3% higher AUPRC. The strong criteria level performance
of COMPOSE provides a good foundation for patient-trial matching.
Table 3: Performance on Criteria Level matching.
Model Accuracy AUROC AUPRC
Baselines
LSTM+GloVe 0.722±0.010 0.789±0.009 0.784±0.009
LSTM+BERT 0.834±0.008 0.845±0.007 0.840±0.007
DeepEnroll 0.869±0.012 0.936±0.013 0.947±0.011
Reduced
COMPOSE-MN 0.899±0.012 0.955±0.013 0.960±0.010
COMPOSE-Highway 0.912±0.007 0.965±0.007 0.967±0.009
COMPOSE-Ld 0.939±0.010 0.976±0.009 0.973±0.007
Proposed COMPOSE 0.945±0.008 0.980±0.007 0.979±0.008
Varying Length of Patient Record It is challenging for matching
patients with longer records due to gradient vanishing issues of
deep learningmodels or evolving health conditions of patients. Here
we experimentally explore how COMPOSE performs in matching
trials with patients who have short or long records. We categorize
patients into three groups based on the length of their EHR records:
Short (1 visit), Medium (2-3 visits), Long (≥ 4 visits). We report the
patient-trial matching performance for each group in Table 4.
Table 4: Performance (measured by accuracy) on trial level
matching for different length of records.
Model Short Medium Long
LSTM+GloVe 0.4906 0.4328 0.0000
LSTM+BERT 0.5484 0.5512 0.5338
Criteria2Query 0.6833 0.5989 0.5172
DeepEnroll 0.6779 0.6797 0.6443
COMPOSE 0.8420 0.8389 0.8350
From Table 4, we can observe that for most models it is eas-
ier to match patients with short and medium length of records
to trials. This is probably due to patients with shorter sequences
tend to have simpler health conditions, while patients with longer
records tend to have more complex condition or condition changes,
which cause their EHR to have irrelevant information that con-
fused the patient-trial matching model. Compared with baselines,
COMPOSE have robust performance for patients with different length
of records, this is because COMPOSE uses dynamic memory network
to store patients’ EHR information, which has better capability to
reserve fine-grained information in different slots.
Q2. Varying Disease Types
We also conduct experiments to explore how our model performs
on different types of diseases. We select trials related to chronic dis-
eases, oncology and rare diseases. Particularly, we consider 19 trials
on 9 chronic diseases including chronic pain, chronic obstructive
pulmonary disease, etc. For oncology trials, we consider 33 trials
on 18 oncologies including gastric cancer, lung cancer, etc. we also
select 5 rare diseases related trials including Glioma, Polymyositis,
etc. More details are provided in Appendix.
From the results in Table 5, COMPOSE generally outperformed
other baseline methods and outperformed best baseline DeepEnroll
by 77.3% relative higher accuracy for chronic diseases. For cancer
and rare diseases cohorts, baseline models fail to match correct
patients. However, Criteria2Query outperforms most baselines be-
cause it requires no training process, therefore insufficient data
does not effect its performance.
For COMPOSE, the performance for matching patients with trials
designed for chronic diseases is lower than the other two disease
types. This is due to patients with chronic diseases often have
complex condition and heterogeneous manifestation. So the criteria
for these diseases often have general descriptions. For example,
most trials in the data are related to chronic pain (47.4%), which
is a common symptom often caused by other diseases. The ECs
for trials on chronic pains often contain vague description such as
Adolescents experiencing chronic pain of any type or Have a history
of non-cancer pain in past 6 months. It is difficult for automatic
matching methods to match patient with such terms likeany type
or non-cancer, thus results in low accuracy.
In contrast, trials on oncology and rare diseases have more strict
criteria in recruiting patients. Most of these ECs requires different
medications and diagnosis from different aspect. Therefore, the task
is much more difficult than common matching tasks for baseline
modes, since these models have to align the patient representation
with each criterion. However, there is little training and testing data
available to finish such a complex task for most baseline models.
We will further discuss this in the case study section.
Table 5: Performance (measured by accuracy) on trial level
matching for different disease types.
Model Chronic Diseases Oncology Rare Diseases
LSTM+GloVe 0.1793 0.0000 0.0000
LSTM+BERT 0.2062 0.0000 0.0000
Criteria2Query 0.5103 0.2722 0.2292
DeepEnroll 0.3345 0.0000 0.0000
COMPOSE 0.5931 0.6370 0.6875
Q3. Varying Trial Phases
From the results in Table 6 , it is easy to see COMPOSE significantly
outperforms other models on different phases. Compared to the best
baseline models DeepEnroll and Criteria2Query, COMPOSE achieves
155% relative higher accuracy for phase I trials, 19% higher accuracy
for phase II trials and 27% higher accuracy for phase III trials.
Compared all phases, the matching performance on Phase I trials
is generally much lower. This is due to phase I trials are designed to
test a new regimen’s tolerability and toxicity. These trials usually
enroll a limited number of patients who have exhausted other
treatment options. Consequently in our training data we also have
much less Phase I trials and fewer patients available for training
and testing: only 5% patients enrolled in phase I trials, while much
more patients are enrolled in phase II (42%) and III trials (53%).
Table 6: Performance (measured by accuracy) on trial level
matching for different trial phases.
Model Phase I Phase II Phase III
LSTM+GloVe 0.0008 0.5865 0.3743
LSTM+BERT 0.0025 0.6045 0.4862
Criteria2Query 0.3025 0.6433 0.5870
DeepEnroll 0.2034 0.7493 0.6329
COMPOSE 0.5189 0.8939 0.8005
Q4. Varying Threshold of Matching
In practice, some inclusion or exclusion criteria can be too strict
to prevent finding patients, yet non-essential thus can be modified.
In this section, we will examine how trial matching accuracy will
change under different matching thresholds. We also show COMPOSE
can provide insights for guiding the adjustment of criteria.
Table 7 shows the performance of trial matching results under
threshold 70%, 80% and 90% (i.e., a pair of patient and trial is consid-
ered matching when the patient matches 70%/80%/90% of criteria
of the trial). Criteria2Query is not applicable for this analysis since
it requires all criteria in a trial to match patients. For COMPOSE, a
more strict matching threshold results in 2% lower accuracy score.
While for baseline models, their performance drops 5%~6% when
the threshold rises from 80% to 90%. When threshold rises from
90% to 100%, performance drops by more than 11%.
In order to explore which criteria cause the performance drop,
we examine three criteria in Tanezumab for Diabetic Peripheral
Neuropathy trial (NCT01087203) : (1) Other types of diabetic neu-
ropathies; (2) Clinically significant neurological diseases; (3) Clini-
cally significant psychiatric diseases. The three criteria are success-
fully matched by COMPOSE, but wrongly matched by other baselines
when the threshold is increased from 0.8 to 1. These criteria de-
scribe general disease cohorts rather than a specific disease. For
baseline models that use RNN to encode medical codes, it is difficult
to align such abstract disease cohort description with detailed codes
in patients’ EHR records such as Diabetes mellitus due to underlying
condition with diabetic polyneuropathy. Thanks to the hierarchi-
cal memory networks to store taxonomies of medical concepts,
COMPOSE can easily align the criteria to either a detailed code or a
more general parent concept.
Table 7: Performance (accuracy) for different thresholds.
Model 70% Matching 80% Matching 90% Matching
LSTM+GloVe 0.6218 0.5862 0.5057
LSTM+BERT 0.7231 0.6861 0.6238
DeepEnroll 0.8225 0.7963 0.7422
COMPOSE 0.9334 0.9193 0.8915
Q5. Case Studies
To show how the attentional record align mechanism in COMPOSE
works, we choose a trial on Cabozantinib which treats grade IV
astrocytic tumors. COMPOSE successfully matches this trial (94%
matching) while all baselines fail (<50% matching). Fig. 3 shows the
attention weights on different memory slots for 6 selected criteria.
Lv1 Lv2 Lv3 Lv4 Lv1 Lv2 Lv3 Lv4 Lv1 Lv2 Lv3Lv4Demo
Diagnosis Medication Procedure
1. received temozolomide therapy
2. receiving warfarin (or other 
coumarin derivatives)
3. acute intracranial/ 
intratumoral hemorrhage.
4. pregnant or breast-feeding
5. serious intercurrent illness
6. inherited bleeding diathesis or 
coagulopathy
Figure 3: Attention weights on the memory slots for the
Cabozantinib trial for treating grade IV astrocytic tumors.
(a) DeepEnroll (b) COMPOSE
Figure 4: Visualize EHR and EC embeddings using PCA
For this trial, each criterion focuses on a single diagnosis or
medication, so it is difficult for baseline models to match each
criterion to a longer patient record. However, the attentional record
align mechanism in COMPOSE helps each criterion match the most
related memory slots and therefore achieves dynamic matching.
For example, the 4th criteria (pregnant or breast-feeding) is aligned
to the demographic slot. And the 2nd EC (receiving warfarin or other
coumarin derivatives) is aligned to the Lv.2 and Lv.4 of medication
slots since warfarin corresponds to a detailed medication while
coumarin derivatives corresponds to a higher level category.
We also visually compared the learned embeddings from COMPOSE
and DeepEnroll using principal component analysis (PCA) in Fig
4. For DeepEnroll, a patient (green circle) is aligned to multiple
inclusion and exclusion criteria (squares and triangles), so the EC
embeddings are mixed and lead to wrong prediction. However,
for COMPOSE, we use each EC as queries to match EHR records, so
there are many EHR embeddings (blue and red circles) and each
embedding is corresponding to a specific EC. So the model can have
more accurate matching for different ECs. Besides, the inclusion
and exclusion EC embeddings form different clusters, which means
the model can differentiate them by optimizing the distance.
We also found some trials difficult to find matching patients,
e.g., the trial for Nivolumab Plus Ipilimumab or Nivolumab Plus
Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small
Cell Lung Cancer (NSCLC, NCT02998528). All models achieve lower
than 50% accuracy score for this trial. The ECs in this trial are listed
in Appendix B, and we denotes inclusion criteria as I and exclusion
criteria as E. The prediction results of COMPOSE for this trial and a
case patient are shown in Fig 5.
𝑰𝑰𝟏𝟏 𝑰𝑰𝟐𝟐 𝑰𝑰𝟑𝟑 𝑰𝑰𝟒𝟒 𝑬𝑬𝟏𝟏 𝑬𝑬𝟐𝟐 𝑬𝑬𝟑𝟑
Mismatch
Match
Unknown
Figure 5: Prediction results for NCT02998528 trial. Inclusion
criteria are denoted as I and exclusion criteria as E.
The results show that COMPOSE successfully matches I1 and E3 to
the patient but classifies other ECs to unknown. E1 and E2 describes
a large group of diseases that models fail to match them to either a
detailed code or a category. For I2, I3 and I4, EHR data is not enough
to determine whether a patient matches these criteria.
6 CONCLUSION
In this work, we propose a cross-modal pseudo-siamese network
model, COMPOSE, to conduct patient-trial matching. COMPOSE can
perform dynamic patient-trial matching based on learning taxon-
omy guidedmulti-granularitymedical concept embedding. COMPOSE
is also augmented by a composite loss term to maximize the sim-
ilarity between patient records and inclusion criteria while mini-
mize the similarity between patient records and exclusion criteria.
Experiments on real-world datasets demonstrated that COMPOSE
significantly outperforms state-of-the-art baselines.
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A DETAILS OF TRIAL DATA
The basic statistics of the trial dataset and EHR dataset are shown in
Table 8. The detailed diseases in different cohorts and the number
of trials and patients for each disease are shown in Table 9.
Table 8: Data statistics
Statistic
# of trials 590
Avg. # of Inclusion criteria per trial 6.67
Avg. # of Exclusion criteria per trial 10.56
Avg. criteria sentence length 31.80
# of patients 83,371
# of unique medications 286
# of unique diagnosis 421
# of labeled pairs 397,321
Avg. # of trials per patient 1.20
Avg. # of patients per trial 169.49
Table 9: Diseases in different cohorts
Cohort Disease # of trials # of patients
Rare
Polymyositis 1 11
Glioblastoma 1 16
Diffuse Large B-Cell Lymphoma 1 2
Glioma 1 2
Gastrointestinal Stromal Tumors 1 1
Oncology
Brain and Central Nervous System Tumors 1 60
Unspecified Adult Solid Tumor 1 1
Astrocytic Tumors 1 19
Advanced Solid Tumor 7 9
Ovarian Cancer 1 5
cMET-dysregulated Advanced Solid Tumors 1 1
Triple Negative Breast Cancer 1 2
Cancer 1 1
Non Small Cell Lung Cancer 6 6
Metastatic Colorectal Cancer 1 1
Colorectal Cancer 2 4
Tumors 2 2
Solid Tumor 3 3
PIK3CA Mutated Advanced Solid Tumors 1 1
mCRPC 1 2
Advanced or Metastatic Breast Cancer 1 2
Gastrointestinal Stromal Tumors 1 1
Advanced Gastric Cancer 1 1
Chronic
Chronic Demyelinating Polyradiculoneuropathy 1 56
Chronic Low Back Pain 2 43
Chronic Cluster Headache 3 49
Chronic Pain 4 20
Chronic Sinusitis With or Without Nasal Polyps 1 13
Chronic Myeloid Leukemia 3 5
Hepatitis C, Chronic 3 5
Chronic Severe Plaque-type Psoriasis 1 45
Treatment for Prevention of Chronic Migraine 1 21
B INCLUSION AND EXCLUSION CRITERIA
FOR NCT02998528 TRIAL
All criteria in NCT02998528 trial is shown below. I denotes the
inclusion criteria and E denotes the exclusion criteria.
• I1: Early stage IB-IIIA, operable non-small cell lung cancer,
confirmed in tissue
• I2: Lung function capacity capable of tolerating the proposed
lung surgery
• I3: Eastern Cooperative Oncology Group (ECOG) Perfor-
mance Status of 0-1
• I4: Available tissue of primary lung tumor
• E1: Presence of locally advanced, inoperable or metastatic
disease
• E2: Participants with active, known or suspected autoim-
mune disease
• E3: Prior treatment with any drug that targets T cell co-
stimulations pathways (such as checkpoint inhibitors)
C IMPLEMENTATION DETAILS
All methods are implemented in PyTorch [21] and trained on an
Ubuntu 16.04 with 64GB memory and a Tesla V100 GPU. We use
Adam optimizer [18] with a learning rate of 0.001. We use a batch
size of 512 and train all model for 20 epochs.
For hyper-parameter settings of each baseline model, our prin-
ciple is as follows: For some hyper-parameter, we will use the rec-
ommended setting if it is available in the original paper. Otherwise,
we determine its value by grid search on the validation set.
• LSTM+GloVe.We use 300 dimensional GloVe embedding [22]
as word embedding and max-pooling as sentence embedding
method. Out-of-vocabulary (OOV) words are hashed to one
of 100 random embedding each initialized to mean 0 and
standard deviation 1. The hidden units of LSTM cell are set
to 256.
• LSTM+BERT. The hidden units of LSTM cell are set to 512.
We use the same pretrained clinicalBERT model in COMPOSE.
• Criteria2Query. We directly use the existing model to pro-
duce the matching results for given trials and patients. This
baseline does not require any training process or hyper-
parameters.
• DeepEnroll. We use the recommended settings in the pa-
per. However, to be fair, we use the same BERT model for
DeepEnroll and our model.
• COMPOSE. We set the dimension of all convolutional layers
to 128. The kernel size k1 to k4 is set to 1, 3, 5, 7, and we
use kernel size 3 for the highway layers. The hidden units of
memory slots are set to 320. The margin α in loss term Ld
is set to 0.3.
